Clinical Trials Logo

Myeloid Malignancies clinical trials

View clinical trials related to Myeloid Malignancies.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05807659 Recruiting - Clinical trials for Myeloid Malignancies

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Start date: March 16, 2023
Phase: Phase 2
Study type: Interventional

The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer are: - The safety and efficacy of fractionated busulfan Combined With Chidamide/Fludarabine/Cytarabine(ChiFAB) conditioning regimen in increasing the overall survival rate in patients with non-remission myeloid malignancies after allo-HSCT. - The efficacy of fractionated busulfan conditioning regimen in reducing the recurrence rate in patients with non-remission myeloid malignancies after allo-HSCT. Participants will receive fractionated busulfan-based ChiFAB conditioning regimen (busulfan 3.2mg/kg d-13, -12, 1.6mg/kg d-6~-3, fludarabine 35mg/m2 d-6~-2, cytarabine 1g/m2,d-6~-2, chidamide 30mg d-13,-10,-6,-3) before allo-HSCT.

NCT ID: NCT05796570 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

MORE
Start date: April 19, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: - Decitabine (a nucleoside metabolic inhibitor) - Filgrastim (a recombinant granulocyte colony-stimulating factor (G-CSF)

NCT ID: NCT05775406 Recruiting - Clinical trials for Advanced Solid Tumors

Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.

NCT ID: NCT05115630 Recruiting - Clinical trials for Acute Myeloid Leukemia

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Start date: April 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). KDS-1001 is a study product created using certain immune cells called natural killer (NK) cells collected from a third-party donor.

NCT ID: NCT02958397 Recruiting - Clinical trials for Myeloid Malignancies

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The overall purpose of this study is to explore the therapeutic effect of CD33-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.

NCT ID: NCT02958384 Recruiting - Clinical trials for Myeloid Malignancies

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The overall purpose of this study is to explore the therapeutic effect of LeY-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of myeloid malignancies.